To further improve the drugs delivery system and pharmacokinetics profiles, we co-encapsulated the EGFR drugs and integrin αvβ3 inhibitors to achieve enhanced anti-cancer effects and reduced systemic toxicity. Here, EGFR is linked to cancer.